New Jersey’s Merck & Co (NYSE: MRK) has reportedly backed away from taking a biosimilar follow-on product to market in the USA, despite already having tentative approval to do so from the US Food and Drug Administration.
The insulin glargine product, which was to have been sold as Lusduna, would have faced significant headwinds in a saturated and mature market. Others, such as Danish diabetes giant Novo Nordisk (NOV: N) have faced similar pressures.
According to a stock exchange filing, the American company will be forced to shell out over $150 million to its South Korean development partner Samsung Bioepis to terminate the project.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze